Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism …
L Gaohua, X Miao, L Dou - Expert opinion on drug metabolism & …, 2021 - Taylor & Francis
Introduction: Physiological pH and chemical pKa are two sides of the same coin in defining
the ionization of a drug in the human body. The Henderson-Hasselbalch equation and pH …
the ionization of a drug in the human body. The Henderson-Hasselbalch equation and pH …
The association between proton pump inhibitor use and systemic anti‐tumour therapy on survival outcomes in patients with advanced non‐small cell lung cancer: A …
N Wei, B Zheng, W Que, J Zhang… - British Journal of Clinical …, 2022 - Wiley Online Library
Aims Proton pump inhibitors (PPIs) are often prescribed to prevent or treat gastrointestinal
disease. Whether the combination of systemic anti‐tumour therapy and PPIs leads to poor …
disease. Whether the combination of systemic anti‐tumour therapy and PPIs leads to poor …
[HTML][HTML] Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis
X Du, W Liu, K Chen, Z Wang, X Li, L Yang… - Frontiers in …, 2022 - frontiersin.org
Background The use of gastric acid suppressants (GASs) has an influence on the exposure
of some epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and …
of some epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and …
Concomitant Gastric Acid Suppressants on the Survival of Patients with Non‐Small‐Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine …
J Xia, J Zhu, L Li, S Xu - International Journal of Clinical …, 2022 - Wiley Online Library
Background. The influence of concomitant use of gastric acid suppressants (AS) on survival
of patients with non‐small‐cell lung cancer (NSCLC) treated with epidermal growth factor …
of patients with non‐small‐cell lung cancer (NSCLC) treated with epidermal growth factor …
[HTML][HTML] Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non …
W Sim, SR Jain, WH Lim, YH Chin, CH Ng… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy …
increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy …